Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

By Trey Thoelcke Published Feb 16, 9:40AM EST

Quick Read

EyePoint (EYPT), Janux (JANX), Kyverna (KYTX), and Viking (VKTX) have analyst targets implying 179% to 384% upside.
Janux and Kyverna hold the highest upside projections at 384% and 308% respectively, with unanimous Buy ratings.
Viking advances both oral and injectable obesity drug formulations into Phase 3 with over 4,500 patients enrolled.

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year — © gorodenkoff / iStock via Getty Images

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their late-stage pipelines and upcoming catalysts have convinced institutional investors to build substantial positions. All four trade with unanimous or near-unanimous Buy ratings, a rare show of conviction in volatile biotech.

EyePoint Pharmaceuticals: Retinal Disease Play With Pivotal Trials Starting

EyePoint Pharmaceuticals (NASDAQ: EYPT) trades at $12.94 against a consensus target of $36.08, implying 179% upside. Lead candidate Duravyu combines vorolanib with proprietary Durasert E technology to target both VEGF and IL-6 pathways in diabetic macular edema and wet age-related macular degeneration. Pivotal Phase 3 trials are initiating, with patient dosing beginning in Q1 2026.

EyePoint is positioned as the potential first-to-market tyrosine kinase inhibitor for these indications. Q3 2025 revenue of $5.33 million declined from $10.52 million a year earlier, while net loss reached $59.4 million. Cash stands at $71.1 million. All 13 analysts rate it Buy or Strong Buy. The stock doubled over the past year, gaining 105%, though it pulled back 29% year-to-date.

Janux Therapeutics: Immunotherapy Platform With Massive Upside

Janux Therapeutics (NASDAQ: JANX) trades at $13.14 with a consensus target of $63.59, representing 384% potential upside. The proprietary TRACTr and TRACIr platforms enable tumor-activated T-cell engagement, with two clinical candidates advancing: JANX007 for prostate cancer and JANX008 for solid tumors.

Q3 2025 revenue of $10.0 million surged from $439,000 a year earlier, with net loss of $24.31 million. R&D expenses nearly doubled to $34.63 million from $18.61 million, reflecting accelerated clinical activity. Cash position: $989 million. All 19 analysts rate it Buy or Strong Buy.

Kyverna Therapeutics: CAR T-Cell Therapy for Autoimmune Diseases

Kyverna Therapeutics (NASDAQ: KYTX) trades at $7.26, with analysts targeting $29.60, implying 308% upside. Lead candidate KYV-101 is advancing through late-stage trials for stiff person syndrome and myasthenia gravis, with topline data for stiff person syndrome released ahead of schedule.

Q3 2025 net loss of $36.8 million, or $0.85 per share, beat estimates of -$0.95. The company secured a $150 million loan facility to supplement $171.1 million in cash. Positive interim Phase 2 data in generalized myasthenia gravis supports the clinical thesis. All six analysts rate it Buy or Strong Buy. The stock surged 139% over the past year.

Viking Therapeutics: Obesity Market Contender With Dual Formulation Advantage

Viking Therapeutics (NASDAQ: VKTX | VKTX Price Prediction) trades at $29 against a consensus target of $92.72, representing 220% upside. Lead drug VK2735, a dual GLP-1/GIP agonist, is advancing through Phase 3 VANQUISH trials with over 4,500 patients enrolled in VANQUISH-1 and VANQUISH-2 nearing enrollment completion in Q1 2026. Phase 2 data showed 14.7% weight loss with subcutaneous dosing and 12.2% with oral formulation.

Viking holds a unique position as the only dual agonist with both injectable and oral formulations in development, with the oral version advancing to Phase 3 in Q3 2026. Q4 2025 net loss of $157.7 million, or $1.38 per share, missed estimates of -$0.90 as R&D expenses surged to $153.5 million from $31 million a year earlier. It has cash of $706 million. Of 18 analysts, 17 rate it Buy or Strong Buy, with one Hold.

Balancing Risk and Reward in Biotech

These four stocks represent high-conviction bets on clinical-stage assets approaching commercialization. Viking’s positioning in the obesity market offers the largest potential opportunity, while Kyverna’s first-in-class CAR T approach addresses significant unmet needs in autoimmune diseases. Janux’s platform technology and substantial cash provide multiple shots on goal. EyePoint offers a more mature pipeline with near-term catalysts. All four carry inherent clinical-stage risks including trial failures, regulatory setbacks, and cash burn, but their unanimous or near-unanimous analyst support suggests Wall Street sees asymmetric risk-reward profiles favoring patient investors willing to weather volatility through upcoming data readouts.

About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.